Item 5e. Other matters arising from the international drug control treaties Chair: We will continue agenda item 5e to elect the second co-chair of the expert panel. I recall that there are two co-chairs selected, one by the CND and one Secretary General. It should be chosen with consideration to balanced representation and diverse policy …
United States of America
Plenary – Wednesday morning session
Item 5b: Challenges and future work of the Commission on Narcotic Drugs, the World Health Organization and the International Narcotics Control Board in the review of substances for possible scheduling recommendations. Chair: I have the pleasure to chair the plenary today on behalf of Ambassador Hovhannisyan . It will take place without interpretation today. Due …
Plenary – Monday morning session
Item 1. Election of Officers Chair: Chair: It’s a great honour to welcome you to the 69th session of the CND and for me to chair the CND. It’s the first time that Armenia holds the chair over CND and I would like to thank you for the support and trust. No country can tackle the …
Item 6. Follow-up to the implementation at the national, regional and international levels of all commitments, as reflected in the Ministerial Declaration of 2019, to address and counter the world drug problem.
(…) UNODC: Thank you, Mr. Chair, distinguished delegates, ladies and gentlemen. It is my pleasure to brief the Commission on some of the significant efforts UNODC has undertaken over the last year to confront the global drug problem, in line with the Ministerial Declaration of 2019. Given time constraints, I will highlight just a few …
Item 5. Implementation of the international drug control treaties (Tuesday morning)
Chair: We will consider scheduling recommendations by WHO and INCB. CND Secretariat: Recalls the substances and scheduling recommendations. Chair: Explains process to schedule substances under 1961, 1971 and 1988 conventions. Butonitazene WHO: Butonitazene, or butoxynitazene, is a benzimidazole-derived synthetic opioid not currently under international control and lacking recognized therapeutic use. It appears as a crystalline …
Item 3. High-level segment (Friday morning)
Canada: Esteemed Chair, Ministers, Heads of Delegation, Distinguished Delegates, and Civil Society Representatives: Canada is experiencing one of the most serious public health crises in our country’s history: an unrelenting toxic drug and overdose crisis. The impact and scope of the toxic drug crisis is devastating and more complex than ever. Tragically, we have seen …